论文部分内容阅读
80年代,国家医药管理局提出了以“新产品、新技术、外向型”为基本内容的“医药行业利用外资指导三原则”,开始了医药业的大规模引进外资。与其他行业相比,制药业的进入门槛要高得多,因为一种新药从研发到上市的投入将近8亿美金。中国大多数医药企业都没有自己的专利药品,这给外资进入提供了前提。二十多年来,上海施贵宝、西安杨森、天津史克、重庆葛兰素、无锡华瑞、苏州胶囊、大连辉瑞、杭州默沙东、北京诺华、费森尤斯、上海罗氏等合资或独资企业相继落成,拉开了跨国制药大鳄瓜分中国市场的序幕。
In the 1980s, the State Pharmaceutical Administration proposed the “Three Guiding Principles for Utilizing Foreign Capital in the Pharmaceutical Industry” based on “new products, new technologies and export-oriented products” and started the large-scale introduction of foreign investment in the pharmaceutical industry. Compared to other industries, the entry barrier to the pharmaceutical industry is much higher, because a new drug has invested nearly 800 million dollars from R & D to going public. Most Chinese pharmaceutical companies do not have their own patented drugs, which provides the premise for foreign investment. More than 20 years, Shanghai Squibb, Xi’an Janssen, Tianjin Shi Ke, Chongqing GSK, Wuxi Huarui, Suzhou capsule, Dalian Pfizer, Hangzhou Merck, Beijing Novartis, Fresenius, Shanghai Roche and other joint ventures or wholly-owned enterprises have Completed, opened the prelude to the multinational pharmaceutical predators carving up the Chinese market.